Nuvation Bio Inc. Increase (Decrease) in Accrued Liabilities
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Accrued Liabilities of $1.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $13.77M, a 12892.45% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$12.32M.
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $12.60M, a 72.00% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $8.58M, a 142.95% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $12.35M, a 80.61% increase from fiscal 2024.
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $6.84M.
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$23.00K.
- Nuvation Bio Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$2.32M, a 131.15% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 2 month | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $13.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.45M 10-Q · filed 2026-08-06 | $14.06M derived: sum of 3 quarters · filed 2026-08-06 | $22.64M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$12.32M 10-Q · filed 2026-05-04 | $285.00K derived: sum of 2 quarters · filed 2026-05-04 | $8.87M derived: sum of 3 quarters · filed 2026-05-04 | $8.97M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $12.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $21.18M derived: sum of 2 quarters · filed 2026-03-02 | $21.29M derived: sum of 3 quarters · filed 2026-08-06 | $12.35M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $8.69M derived: sum of 2 quarters · filed 2026-08-06 | -$254.00K 10-Q · filed 2025-11-03 | $7.07M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$8.84M 10-Q · filed 2026-08-06 | -$1.51M derived: sum of 3 quarters · filed 2026-08-06 | $2.02M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$8.94M 10-Q · filed 2026-05-04 | -$1.61M derived: sum of 2 quarters · filed 2026-05-04 | $1.92M derived: sum of 3 quarters · filed 2026-05-04 | -$3.61M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $10.86M derived: sum of 2 quarters · filed 2026-03-02 | $5.33M derived: sum of 3 quarters · filed 2026-03-02 | $6.84M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$2.00M derived: sum of 2 quarters · filed 2025-11-03 | -$490.00K 10-Q · filed 2025-11-03 | -$2.55M derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | -$5.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$4.02M 10-Q · filed 2025-08-07 | -$6.08M derived: sum of 3 quarters · filed 2025-08-07 | -$3.78M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $1.51M 10-Q · filed 2025-05-07 | -$552.00K derived: sum of 2 quarters · filed 2025-05-07 | $1.75M derived: sum of 3 quarters · filed 2025-05-07 | $2.94M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $241.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.43M derived: sum of 3 quarters · filed 2025-03-06 | -$23.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $3.49M derived: sum of 2 quarters · filed 2024-11-06 | $2.04M 10-Q · filed 2024-11-06 | $1.94M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$264.00K 10-Q · filed 2024-08-05 | -$364.00K derived: sum of 3 quarters · filed 2024-08-05 | $1.95M derived: sum of 4 quarters · filed 2024-08-05 | |
| 2023-03-31 | -$1.45M 10-Q · filed 2024-05-14 | -$1.55M derived: sum of 2 quarters · filed 2024-05-14 | $758.00K derived: sum of 3 quarters · filed 2024-05-14 | $1.24M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.21M derived: sum of 2 quarters · filed 2024-02-29 | $2.69M derived: sum of 3 quarters · filed 2024-02-29 | -$2.32M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.79M derived: sum of 2 quarters · filed 2023-11-02 | -$2.22M 10-Q · filed 2023-11-02 | $1.77M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | $483.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$4.53M 10-Q · filed 2023-08-03 | -$542.00K derived: sum of 3 quarters · filed 2023-08-03 | $2.07M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | -$5.02M 10-Q · filed 2023-05-04 | -$1.02M derived: sum of 2 quarters · filed 2023-05-04 | $1.59M derived: sum of 3 quarters · filed 2023-05-04 | $3.14M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $3.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $6.60M derived: sum of 2 quarters · filed 2023-03-15 | $8.15M derived: sum of 3 quarters · filed 2023-03-15 | $7.45M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.16M derived: sum of 2 quarters · filed 2022-11-03 | $3.46M 10-Q · filed 2022-11-03 | $5.00M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $850.00K 10-Q · filed 2022-08-04 | $2.39M derived: sum of 3 quarters · filed 2022-08-04 | $2.49M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$701.00K 10-Q · filed 2022-05-09 | $841.00K derived: sum of 2 quarters · filed 2022-05-09 | $943.00K derived: sum of 3 quarters · filed 2022-05-09 | $2.13M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.64M derived: sum of 2 quarters · filed 2022-02-28 | $2.83M derived: sum of 3 quarters · filed 2022-02-28 | $2.92M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.29M derived: sum of 2 quarters · filed 2021-11-10 | $1.38M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.00K 10-Q · filed 2020-08-14 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.28M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $87.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |